CStone’s Commercialization Capacity Put to Test With Latest Drug Approval
Company’s four drug approvals in a year will contribute major revenue, but will also challenge CStone’s ability to commercialize its products Key takeaways: Its rollout of four new drugs will…
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK -
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- As Covid drug cash dwindles, Vigonvita targets new remedies
- Innogen Pharma jostles for a slice of the weight-loss market
